Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Radiology, Northwest Clinics, Alkmaar, The Netherlands.
Eur Radiol. 2024 Apr;34(4):2512-2523. doi: 10.1007/s00330-023-10085-5. Epub 2023 Oct 12.
The pharmacokinetics of contrast media (CM) will determine how long safe waiting intervals between successive CT or MRI examinations should be. The Contrast Media Safety Committee has reviewed the data on pharmacokinetics of contrast media to suggest safe waiting intervals between successive contrast-enhanced imaging studies in relation to the renal function of the patient. CLINICAL RELEVANCE STATEMENT: Consider a waiting time between elective contrast-enhanced CT and (coronary) angiography with successive iodine-based contrast media administrations in patients with normal renal function (eGFR > 60 mL/min/1.73 m) of optimally 12 h (near complete clearance of the previously administered iodine-based contrast media) and minimally 4 h (if clinical indication requires rapid follow-up). KEY POINTS: • Pharmacokinetics of contrast media will guide safe waiting times between successive administrations. • Safe waiting times increase with increasing renal insufficiency. • Iodine-based contrast media influence MRI signal intensities and gadolinium-based contrast agents influence CT attenuation.
对比剂(CM)的药代动力学将决定连续 CT 或 MRI 检查之间的安全等待时间应该是多久。对比剂安全委员会审查了对比剂药代动力学的数据,以建议根据患者的肾功能,在连续的对比增强成像研究之间的安全等待时间。临床相关性陈述:在肾功能正常(eGFR>60 mL/min/1.73 m)的患者中,考虑在择期碘基对比剂增强 CT 和(冠状动脉)血管造影之间进行等待时间,连续碘基对比剂给药的最佳时间为 12 小时(先前给予的碘基对比剂完全清除),最小时间为 4 小时(如果临床指征需要快速随访)。要点:•对比剂的药代动力学将指导连续给药之间的安全等待时间。•安全等待时间随肾功能不全的增加而增加。•碘基对比剂会影响 MRI 信号强度,而钆基对比剂会影响 CT 衰减。